Latest Breaking News On - Michael recht - Page 1 : vimarsana.com

Investment firm makes majority equity investment in Demakes

The current leadership will stay on to manage the company.

Timothy demakesAndrew demakesElias demakesMichael rechtDemakes enterprisesTowerbrook capital partnersHold neighborhoodWaterhill organicsThinn trimMeat and poultryMeat amp poultryMeat and poultry magazineMeatpoultry comMeat amp poultry magazineMeat newsPoultry news

TowerBrook Capital Partners Announces Majority Investment in Specialty Protein Products Manufacturer Demakes Enterprises

TowerBrook Capital Partners Announces Majority Investment in Specialty Protein Products Manufacturer Demakes Enterprises
perishablenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from perishablenews.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomNew yorkTimothy demakesAndrew demakesArentfox schiffElias demakesMichael rechtSidley austinMonroe capitalDemakes enterprisesWells fargo bank national associationB corporationCredit group of ares managementHold neighborhood

Uptake of new hemophilia gene therapies slow as field assesses options

By Deena Beasley (Reuters) - High cost, logistical issues and the prospect of potential treatment advances are holding back adoption of the first gene.

San diegoUnited statesMichael rechtCaroline humerBob lojewskiBiomarin roctavianMargaret ragniDeena beasleyNational bleeding disorders foundationAmerican society of hematologyUniversity of pittsburghAmerican societyReporting by deena beasleyBill berkrot

TowerBrook Capital invests in US deli meat producer Demakes

Investment firm TowerBrook Capital Partners has acquired a majority stake in US-based deli meats producer Demakes Enterprises.

Andrew demakesMichael rechtTimothy demakesCompany profileCompany profilesDemakes enterprisesWaterhill naturalsTowerbrook capital partnersMassachusetts based demakes enterprisesHold neighborhood

Uptake of new hemophilia gene therapies slow as field assesses options

High cost, logistical issues and the prospect of potential treatment advances are holding back adoption of the first gene therapies for hemophilia, experts said this week during the American Society.

San diegoUnited statesMichael rechtBob lojewskiMargaret ragniCaroline humerBiomarin roctavianAmerican society of hematologyNational bleeding disorders foundationUniversity of pittsburghAmerican societyReporting by deena beasley editingBill berkrot